Abbott Laboratories beat expectations with a quarterly profit thanks to strong medical device sales.

Sales of glucose monitoring products were particularly strong.

An increase in demand for medical interventions supported overall growth.

Annual earnings of 98 cents per share beat analysts' estimates by 3 cents.

Abbott Laboratories $ABT+2.0% raised its full-year forecast to $4.55 to $4.70 per share.

This is a speculative and smaller position in my portfolio but it has paid off so far, what do you think of the results and how do you like the company?

ABT
$102.03 $1.96 +1.96%
Fair Price: $62.37
Ltystrhv: 6.23%
Undervalued
Overvalued
Dostupné pouze členům Bulios Black

No comments yet
Timeline Tracker Overview